The global cardiovascular disease drugs market is anticipated to grow at a significant CAGR during the forecast period (2022-2028). Cardiovascular diseases are caused due to abnormal cardiac structure and function. These diseases are a range of chronic progressive disorders that affect the blood pumping capacity of the heart muscles, leading to an insufficient supply of blood to the whole body. Cardiovascular diseases have a significant burden on the global healthcare system, affecting more than 26 million people across the globe. It is estimated that heart failure across the globe had cost around $100 billion in 2012. Among these, the growing global population suffering from cardiovascular illnesses is the primary factor for the increased demand for cardiovascular disease drugs. This is the primary factor contributing to the global cardiovascular disease drugs market.

Globally, almost 15 million people suffer from heart attacks or similar issues, according to the World Heart Federation. Heart disease claims the lives of around 659,000 people in the US each year, accounting for one out of every four mortalities. Between 2016 and 2017, the US spent $363 billion on heart disease. This covers the costs of healthcare services, medications, and lost productivity as a result of mortality. The most frequent type of heart illness, coronary heart disease, affects approximately 18.2 million persons aged 20 and up (about 6.7%). Adults under the age of 65 account for about 2 out of every 10 mortalities due to coronary artery disease. These estimates lead to an increased demand for effective solutions such as cardiovascular disease drugs, thereby augmenting the global cardiovascular disease drugs market.

Market Coverage

• The market number available for – 2021-2028

• Base year- 2021

• Forecast period- 2022-2028

• Segment Covered- 

o By Drug Class

o By Disease Indication

• Regions covered-

o North America

o Europe

o Asia-Pacific

o Rest of the World

• Competitive Landscape:  Amgen Inc., Pfizer Inc., and Baxter International Inc., among others.

Key questions addressed by the report

• What is the market growth rate?

• Which segment and region dominate the market in the base year?

• Which segment and region will project the fastest growth in the market?

• How COVID-19 impacted the market?

o Deviation from the pre-COVID-19 forecast

o Most affected region and segment

• Who is the leader in the market?

• How are players addressing challenges to sustain growth?

• Where is the investment opportunity?

Global Cardiovascular Disease Drugs Market Report by Segment

By Drug Class 

• Anti-Hyperlipidemics

• Anticoagulants

• Anti-Arrhythmics

• Others

By Disease Indication

• Coronary Artery Disease

• Arrhythmia

• Hypertension

• Hyperlipidemia

• Others

Global Cardiovascular Disease Drugs Market Report by Region

North America       

• US

• Canada

Europe

• Germany

• UK

• France

• Spain

• Italy

• Rest of Europe

Asia-Pacific    

• China

• Japan

• India

• Rest of Asia-Pacific

Rest of the World

• Latin America

• Middle East and Africa